Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

Apimeds Pharmaceuticals US, Inc.

CIK 1894525 APUS·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

  1. Late filing NT 10-K
  2. Going concern 10-K +34d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Going concern Filing comparison

Apimeds Pharmaceuticals US, Inc. disclosed substantial doubt about its ability to continue as a going concern

No going-concern disclosure → Substantial doubt about ability to continue as a going concern

As of March 31, 2026, the Company has drawn a total amount of $10,900,000 from the PIPE (see note 6) wherein $8,000,000 in proceeds have been recorded as restricted cash. Ther can be no assurance that the Company will be able to draw funds from the PIPE at terms acceptable to it or at all. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not contain any adjustments that might result from the outcome of this uncertainty. Use of Estimates The preparation of financial statements in conformity…
Evidence
Blank check
No
Comparable
Yes
Current state
substantial_doubt
Current state label
Substantial doubt about ability to continue as a going concern
Direction
escalated
Located in
filing body
Prior filed
2025-11-12
Prior form
10-Q
Prior state
none
Prior state label
No going-concern disclosure
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗

Late filing Filing comparison

Apimeds Pharmaceuticals US, Inc. told the SEC it could not file its quarterly report on time

Does not expect a significant change in results. Filed on the statutory due date.

Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 (the “Form 10-Q”) by the prescribed due date because the Company is in the process of finalizing the financial statements for the fiscal quarter ended March 31, 2026, and will need additional time to complete such financial statements.
Evidence
Anticipates significant change
No
Days past due date
0
Other periodic reports filed
Yes
Routine
Yes
Severity
normal
Source
Form 12b-25 (notification of late filing)
Stated reason
Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 (the “Form 10-Q”) by the prescribed due date because the Company is in the process of finalizing the financial statements for the fiscal quarter ended March 31, 2026, and will need additional time to complete such financial statements.
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗

Going concern Filing comparison

Apimeds Pharmaceuticals US, Inc. disclosed substantial doubt about its ability to continue as a going concern

No going-concern disclosure → Substantial doubt about ability to continue as a going concern

As of December 31, 2025, our accumulated deficit was $10.3 million. We expect to continue to incur significant operating losses as we advance the clinical development of Apitox and build our operational infrastructure. Significant manufacturing costs related to Apitox development are expected to be incurred beginning in the first quarter of 2026 and throughout the year. These conditions raise substantial doubt about our ability to continue as a going concern. Management’s primary plan to address near-term liquidity needs is the continued execution of additional tranches under the Securities…
Evidence
Blank check
No
Comparable
Yes
Current state
substantial_doubt
Current state label
Substantial doubt about ability to continue as a going concern
Direction
escalated
Located in
going-concern note
Prior filed
2025-05-02
Prior form
10-K/A
Prior state
none
Prior state label
No going-concern disclosure
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗

Late filing elevated Filing comparison

Apimeds Pharmaceuticals US, Inc. told the SEC it could not file its annual report on time

Does not expect a significant change in results. Filed on the statutory due date.

Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fourth quarter and fiscal year ended December 31, 2025 (the “2025 Form 10-K”) by the prescribed due date because the Company is in the process of preparing the financial statements for the fourth quarter and fiscal year ended December 31, 2025, and will need additional time to complete such financial statements. The Company’s independent registered public accounting firm will also need additional time to complete its review and audit of the financial statements for the fourth quarter and fiscal year…
Evidence
Anticipates significant change
No
Days past due date
0
Other periodic reports filed
Yes
Routine
No
Severity
elevated
Source
Form 12b-25 (notification of late filing)
Stated reason
Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fourth quarter and fiscal year ended December 31, 2025 (the “2025 Form 10-K”) by the prescribed due date because the Company is in the process of preparing the financial statements for the fourth quarter and fiscal year ended December 31, 2025, and will need additional time to complete such financial statements. The Company’s independent registered public accounting firm will also need additional time to complete its review and audit of the financial statements for the fourth quarter and fiscal year…
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗